Hematology
News
Extended half-life clotting factors cut infusions, hike prices
The use of extended half-life clotting factors was able to significantly reduce the number of infusions but the cost went up significantly.
News
HAVEN 4: Monthly emicizumab shows value
Emicizumab was effective as a monthly treatment for patients with hemophilia A, both with and without inhibitors, according to an ongoing phase 3...
Conference Coverage
Study highlights lack of data on transgender leukemia patients
NEWPORT BEACH, CALIF. – Researchers identified transgender leukemia patients by detecting gender-karyotype mismatches.
Commentary
Powerful breast-implant testimony constrained by limited evidence
SILVER SPRING, MD. – Women report personal horror stories of apparent breast-implant complications, but systematically-collected data remain...
Video
AUGUSTUS: Dual surpasses triple therapy when AFib patients have PCI or ACS
NEW ORLEANS – Dropping aspirin but keeping anticoagulation with apixaban and antiplatelet clopidogrel was effective and associated with less...
Conference Coverage
Andexanet alfa effectively reverses factor Xa inhibition
HONOLULU – The drug establishes good or excellent hemostasis in 82% of patients with acute major bleeding associated...
Conference Coverage
Repeat VTE risk heightened in HIV patients
SEATTLE – Two studies detail the risk factors of first-time venous thromboembolism and heightened incidence of repeat VTE in patients with HIV.
Conference Coverage
Gene therapy in hemophilia is just version 1.0
PRAGUE – The biggest question for gene therapy today is durability, according to Dr. John Pasi.
Conference Coverage
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...
Conference Coverage
Think duration, not dose, when managing bleeding with non–factor replacements
PRAGUE – The duration of treatment is more strongly linked to thromboembolism than dose magnitude, according to Dr. Andreas Tiede.